TWI693235B - mRNA 展示抗體庫及方法 - Google Patents

mRNA 展示抗體庫及方法 Download PDF

Info

Publication number
TWI693235B
TWI693235B TW107141333A TW107141333A TWI693235B TW I693235 B TWI693235 B TW I693235B TW 107141333 A TW107141333 A TW 107141333A TW 107141333 A TW107141333 A TW 107141333A TW I693235 B TWI693235 B TW I693235B
Authority
TW
Taiwan
Prior art keywords
library
sub
members
cdr1
cdr3
Prior art date
Application number
TW107141333A
Other languages
English (en)
Chinese (zh)
Other versions
TW201922794A (zh
Inventor
安德斯 奧爾森
Original Assignee
美商南特生物科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商南特生物科學股份有限公司 filed Critical 美商南特生物科學股份有限公司
Publication of TW201922794A publication Critical patent/TW201922794A/zh
Application granted granted Critical
Publication of TWI693235B publication Critical patent/TWI693235B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW107141333A 2017-11-20 2018-11-20 mRNA 展示抗體庫及方法 TWI693235B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762588914P 2017-11-20 2017-11-20
US62/588,914 2017-11-20

Publications (2)

Publication Number Publication Date
TW201922794A TW201922794A (zh) 2019-06-16
TWI693235B true TWI693235B (zh) 2020-05-11

Family

ID=66534257

Family Applications (4)

Application Number Title Priority Date Filing Date
TW107141333A TWI693235B (zh) 2017-11-20 2018-11-20 mRNA 展示抗體庫及方法
TW112138352A TWI877823B (zh) 2017-11-20 2018-11-20 具有複數個核酸庫的組成物
TW114105419A TW202521587A (zh) 2017-11-20 2018-11-20 自包括scFv的表現庫成員產生高親和力抗體或抗體片段之方法
TW109109861A TWI821545B (zh) 2017-11-20 2018-11-20 具有複數個核酸庫之組合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW112138352A TWI877823B (zh) 2017-11-20 2018-11-20 具有複數個核酸庫的組成物
TW114105419A TW202521587A (zh) 2017-11-20 2018-11-20 自包括scFv的表現庫成員產生高親和力抗體或抗體片段之方法
TW109109861A TWI821545B (zh) 2017-11-20 2018-11-20 具有複數個核酸庫之組合物

Country Status (11)

Country Link
US (3) US11015188B2 (https=)
EP (3) EP3713964B1 (https=)
JP (2) JP7291700B2 (https=)
KR (2) KR102875544B1 (https=)
CN (2) CN118206640A (https=)
AU (1) AU2018367622B2 (https=)
CA (1) CA3082172C (https=)
ES (1) ES2969081T3 (https=)
IL (2) IL274780B2 (https=)
TW (4) TWI693235B (https=)
WO (1) WO2019099882A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912756B2 (en) 2017-11-20 2024-02-27 Nantbio, Inc. MRNA display antibody library and methods
US12060655B2 (en) 2017-11-20 2024-08-13 Nantbio, Inc. mRNA display antibody library and methods

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113366104B (zh) * 2019-01-31 2024-03-26 南特生物科学公司 mRNA展示抗体文库和方法
WO2021061842A1 (en) * 2019-09-23 2021-04-01 Twist Bioscience Corporation Variant nucleic acid libraries for single domain antibodies
EP4314075A4 (en) 2021-03-24 2025-04-09 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CD3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101548034A (zh) * 2006-10-02 2009-09-30 航道生物技术有限责任公司 多样性合成肽和多肽文库的设计和构建
WO2010054007A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
CN1672160B (zh) * 2002-05-20 2010-06-09 埃博马可西斯公司 基于前导抗体的结构构建抗体文库的方法
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CA2572961C (en) * 2004-07-06 2016-08-16 Bioren, Inc. Universal antibody libraries
GB0500099D0 (en) 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
JP2009515516A (ja) * 2005-11-14 2009-04-16 バイオレン・インク 推定成熟ｃｄｒのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化
US20100137156A1 (en) * 2007-03-09 2010-06-03 Leung Shui-On Construction and use of a functionally human antibody library with maximized repertoire diversity
JP2011507519A (ja) * 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
KR100961392B1 (ko) 2008-04-15 2010-06-07 이화여자대학교 산학협력단 항체 파지 표면제시 라이브러리 제조방법, 상기 방법에의해 제조된 항체 파지 표면제시 라이브러리, 상기 항체파지 표면제시 라이브러리 유전자를 포함한 파지미드 벡터
MX2011003381A (es) * 2008-09-30 2011-04-21 Abbott Lab Metodo mejorado para despliegue de arn.
RU2011117213A (ru) * 2008-09-30 2012-11-10 Эббот Лэборетриз (Us) Улучшенные библиотеки антител
EP2528944B1 (en) 2010-01-29 2015-08-12 MorphoSys AG Rodent combinatorial antibody libraries
KR101694832B1 (ko) 2014-12-31 2017-01-12 앱클론(주) 항체 라이브러리 및 그의 제작방법
EP3246434A1 (en) 2015-01-13 2017-11-22 Ewha University-Industry Collaboration Foundation Method for preparing novel antibody library and library prepared thereby
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
IL274780B2 (en) 2017-11-20 2025-04-01 Nantbio Inc mRNA library for antibody display and methods
US11034951B2 (en) 2017-11-20 2021-06-15 Nantbio, Inc. mRNA display antibody library and methods
CN113366104B (zh) 2019-01-31 2024-03-26 南特生物科学公司 mRNA展示抗体文库和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101548034A (zh) * 2006-10-02 2009-09-30 航道生物技术有限责任公司 多样性合成肽和多肽文库的设计和构建
CN101548034B (zh) 2006-10-02 2013-11-13 航道生物技术有限责任公司 多样性合成肽和多肽文库的设计和构建
WO2010054007A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Weber, Marcel, et al. "A highly functional synthetic phage display library containing over 40 billion human antibody clones." PLoS One 9.6 (2014): e100000. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912756B2 (en) 2017-11-20 2024-02-27 Nantbio, Inc. MRNA display antibody library and methods
US12060655B2 (en) 2017-11-20 2024-08-13 Nantbio, Inc. mRNA display antibody library and methods

Also Published As

Publication number Publication date
EP4368716A3 (en) 2024-08-21
TW202402807A (zh) 2024-01-16
US20210238587A1 (en) 2021-08-05
JP2021503292A (ja) 2021-02-12
IL274780A (en) 2020-07-30
CN111511768B (zh) 2024-03-26
EP3713964C0 (en) 2024-01-17
TWI877823B (zh) 2025-03-21
WO2019099882A2 (en) 2019-05-23
TWI821545B (zh) 2023-11-11
CA3082172C (en) 2022-11-29
EP4368716A2 (en) 2024-05-15
EP4644544A2 (en) 2025-11-05
EP4368716C0 (en) 2026-01-28
CA3082172A1 (en) 2019-05-23
EP3713964A4 (en) 2021-08-18
EP4644544A3 (en) 2025-12-31
WO2019099882A3 (en) 2019-08-01
KR102875544B1 (ko) 2025-10-23
IL274780B2 (en) 2025-04-01
US20190153432A1 (en) 2019-05-23
EP3713964B1 (en) 2024-01-17
EP4368716B1 (en) 2026-01-28
JP7291700B2 (ja) 2023-06-15
ES2969081T3 (es) 2024-05-16
TW202521587A (zh) 2025-06-01
US11912756B2 (en) 2024-02-27
JP2023109916A (ja) 2023-08-08
KR20200075028A (ko) 2020-06-25
TW202045548A (zh) 2020-12-16
IL274780B1 (en) 2024-12-01
IL316884A (en) 2025-01-01
CN118206640A (zh) 2024-06-18
JP7628153B2 (ja) 2025-02-07
EP3713964A2 (en) 2020-09-30
CN111511768A (zh) 2020-08-07
US11015188B2 (en) 2021-05-25
AU2018367622B2 (en) 2022-12-22
AU2018367622A1 (en) 2020-07-02
KR20230174295A (ko) 2023-12-27
US20240190945A1 (en) 2024-06-13
KR102615744B1 (ko) 2023-12-19
TW201922794A (zh) 2019-06-16

Similar Documents

Publication Publication Date Title
TWI693235B (zh) mRNA 展示抗體庫及方法
JP7839238B2 (ja) ｍＲＮＡディスプレイ抗体ライブラリー及び方法
US11034951B2 (en) mRNA display antibody library and methods
US20260018241A1 (en) Methods of isolating anti-ligands
HK40110900A (zh) Mrna展示抗体文库和方法
HK40027625B (en) An mrna display antibody library and methods
HK40027625A (en) An mrna display antibody library and methods
HK40117257A (zh) 分离反配体的方法